These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 15303545

  • 1. [Myelofibrosis with myeloid metaplasia. A study of 24 consecutive patients].
    Bettini R, Redaelli S, Marzetta K, Maino C, Sala D, Saccà V, Gorini M.
    Recenti Prog Med; 2004; 95(7-8):358-64. PubMed ID: 15303545
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Transient promyelocytic expansion in primary myelofibrosis].
    Ishikawa T, Matsushita A, Nagai K, Shimazaki A, Takahashi T.
    Rinsho Ketsueki; 1995 Jul; 36(7):700-2. PubMed ID: 7563600
    [Abstract] [Full Text] [Related]

  • 4. Circulating hematopoietic progenitor cells predict survival in patients with myelofibrosis with myeloid metaplasia.
    Sagaster V, Jäger E, Weltermann A, Schwarzinger I, Gisslinger H, Lechner K, Geissler K, Oehler L.
    Haematologica; 2003 Nov; 88(11):1204-12. PubMed ID: 14607748
    [Abstract] [Full Text] [Related]

  • 5. Myelofibrosis with myeloid metaplasia: diagnosis, prognostic factors, and staging.
    Cervantes F, Barosi G.
    Semin Oncol; 2005 Aug; 32(4):395-402. PubMed ID: 16202685
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemic.
    Meytes D, Katz D, Ramot B.
    Isr J Med Sci; 1976 Jun; 12(6):534-42. PubMed ID: 955869
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction.
    Barosi G, Ambrosetti A, Buratti A, Finelli C, Liberato NL, Quaglini S, Ricetti MM, Visani G, Tura S, Ascari E.
    Leukemia; 1993 Feb; 7(2):200-6. PubMed ID: 8426474
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia.
    Tefferi A, Dingli D, Li CY, Dewald GW.
    Cancer; 2005 Oct 15; 104(8):1656-60. PubMed ID: 16104040
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: a prospective evaluation of prognostic value in 94 patients.
    Arora B, Sirhan S, Hoyer JD, Mesa RA, Tefferi A.
    Br J Haematol; 2005 Jan 15; 128(1):42-8. PubMed ID: 15606548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.